Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers

Oncology Reports

Volumn 25, Issue 5, 2011, Pages 1389-1397

  Lubet, Ronald A ^a   Lu, Yan ^b   Bode, Ann M ^c   You, Ming ^b   Verney, Zoe M ^d   Steele, Vernone E ^a   Townsend, Reid ^c   Juliana, M Margaret ^e   Grubbs, Clinton J ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

Epidermal growth factor receptor inhibitors; Hydroxybutyl(butyl)nitrosamine; Urinary bladder cancer

Indexed keywords

AURORA A KINASE; AURORA B KINASE; BIOLOGICAL MARKER; BUB1 RELATED PROTEIN; CELL CYCLE PROTEIN 20; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOLIN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BUTYLHYDROXYBUTYLNITROSAMINE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; MODELS, BIOLOGICAL; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 79953049622     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1200     Document Type: Article

References (23)

1. Lubet RA, Steele VE, Juliana MM and Grubbs CJ: Screening agents for preventive efficacy in a bladder cancer model: study design, endpoints, and gefitinib and naproxen efficacy. J Urol 183: 1598-1603, 2010.
2. Lubet RA, Yang CS, Lee MJ, et al: Preventive effects of polyphenone E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols. Mol Cancer Ther 6: 2022-2028, 2007. (Pubitemid 47052492)
3. Lubet RA, Huebner K, Fong LY, et al: 4-Hydroxybutyl(butyl) nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis 26: 571-578, 2005. (Pubitemid 41214146)
4. Yao R, Yi Y, Grubbs CJ, Lubet RA and You M: Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9: 207-221, 2007. (Pubitemid 46457238)
5. Williams PD, Lee JK and Theodorescu D: Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 8: 838-846, 2008.
6. Chow NH, Chan SH, Tzai TS, Ho CL and Liu HS: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7: 1957-1962, 2001.
7. Colquhon AJ and Mellon JK: Epidermal growth factor receptor and bladder cancer. Postgrad Med J 78: 584-589, 2002.
8. Baselga J: Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 10: 41-45, 2001.
9. Steele VE, Rao CV, Zhang Y, et al: Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res 2: 951-956, 2009.
10. Alban A, David SO, Bjorkesten L, Anderson C, Sloge E, Lewis C and Currie I: A novel experimental design for comparative two-dimensional gel analysis: two dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomic 3: 36-44, 2003. (Pubitemid 36151066)
11. Bredemeyer AJ, Lewis RM, Malone JD, Davis AE, Gross J, Townsend RR and Ley TJ: A proteomic approach for the discovery of protease substrates. Proc Natl Acad Sci USA 101: 11785-11790, 2004. (Pubitemid 39095372)
12. King JB, Gross J, Lovly CM, Rohrs H, Piwnics-Worms H and Townsend RR: Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal Chem 78: 2171-2181, 2006.
13. Wacnik PW, Baker CM, Herron MJ, et al: Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 115: 95-106, 2005.
14. Strimmer K: A unified approach to false discovery rate estimation. BMC Bioinformatics 9: 303, 2008.
15. Mootha VK, Lindgren CM, Eriksson KF, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 34: 267-273, 2003. (Pubitemid 36792858)
16. Subramanian A, Tamayo P Mootha VK, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550, 2005. (Pubitemid 41528093)
17. Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868, 1998. (Pubitemid 29003722)
18. Unlu M, Morgan ME and Minden JS: Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18: 2071-2077, 2005.
19. Wulfing C, Machiels JR Richel DJ, et al: A single arm, multicenter, open-label phase 2 study of lapatinib as the second line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115: 2881-2890, 2009.
20. Pruthi RS, Nielson M, Heathcote S, et al: A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Inter 106: 349-356, 2010.
21. Sharma MC and Sharma M: The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Current Pharm Design 13: 3568-3575, 2007. (Pubitemid 350238927)
22. Kim LC, Song L and Harua EB: Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6: 587-595, 2009.
23. Kassouf W, Brown GA and Black PC: Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol 180: 1146-1153, 2008.